Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
China launches experimental satellites to advance 6G techSpring Festival holiday sees 474 million domestic tourist trips in ChinaFirst batch of crossXi Meets Chairman of Russian State DumaHong Kong greets 1.3 mln visits during Spring Festival holidayXi Inspects Command Office for East China Sea Area of China Coast GuardXi Pledges to Work with Milei for Sound Development of ChinaCreative accountingCulture Insider: China's Ghost FestivalChina's AG600M firefighting aircraft completes cold
1.8489s , 6491.765625 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Earth Enquirer news portal